Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus CHOP in untreated AITL
NCT03853044Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Dec 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT03853044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853044.